GE
Healthcare initiates
clinical trials for
first-ever PET imaging agent
to track angiogenesis in
cancer-- GE Healthcare,
a division of the General
Electric Company has
announced that it has
initiated a first-in-man
clinical study designed to
validate information
provided by a molecular
imaging agent in evaluating
the extent and nature of
cancer. Specifically, this
proprietary positron
emission tomography (PET)
agent has a biological
mechanism to track the
process of angiogenesis, the
formation of new blood
vessels in the body....more
To
receive news and updates about
Medical Devices and developments in the Arab
World:
